Loading investors…
Ranked by rounds participated in, from announcements in Jul 7, 2026 – Oct 4, 2026. Lead counts include only confirmed lead roles.
New companies 6 · Follow-on 0
Stages: Series A 2, Series B 2, Series C+ 2
Leal Therapeutics $30M Series AAmplifica Holdings Group $26M Series BInduPro $77M Series BNew companies 5 · Follow-on 0
Stages: Series C+ 3, Series B 2
Abcuro $66M Series DEpicrispr Biotechnologies $90M Series CQuantHealth $45M Series BNew companies 4 · Follow-on 0
Stages: Series C+ 2, Series A 1, Undisclosed 1
AusperBio $120M Series CAbcuro $66M Series DInfinimmune $75M Series ANew companies 3 · Follow-on 0
Stages: Series A 2, Series C+ 1
AusperBio $120M Series CBeyang Therapeutics $30M Series ACORE Biomedicine $21M Series ANew companies 3 · Follow-on 0
Stages: Series C+ 3
Epicrispr Biotechnologies $90M Series CAdvanCell $315M Series DAllotera Therapeutics $35M Series CNew companies 3 · Follow-on 0
Stages: Seed 2, Series C+ 1
Vivid Dx $15M SeedMirae $5.4M SeedMoa Technology £22.2M Series CNew companies 2 · Follow-on 0
Stages: Series A 1, Series C+ 1
AusperBio $120M Series CCORE Biomedicine $21M Series ANew companies 2 · Follow-on 0
Stages: Seed 1, Series C+ 1
Transfyr $25M SeedChai Discovery $400M Series CNew companies 2 · Follow-on 0
Stages: Series C+ 2
Abcuro $66M Series DEpicrispr Biotechnologies $90M Series CNew companies 2 · Follow-on 0
Stages: Series B 1, Series C+ 1
Abcuro $66M Series DKhartis Therapeutics $50M Series BNew companies 2 · Follow-on 0
Stages: Series B 1, Series C+ 1
Abcuro $66M Series DCrystalys Therapeutics $130M Series BNew companies 2 · Follow-on 0
Stages: Series A 1, Series B 1
Leal Therapeutics $30M Series AKhartis Therapeutics $50M Series BNew companies 2 · Follow-on 0
Stages: Series A 1, Series B 1
Leal Therapeutics $30M Series AInduPro $77M Series BNew companies 2 · Follow-on 0
Stages: Series A 1, Series B 1
Khartis Therapeutics $50M Series BInfinimmune $75M Series ANew companies 2 · Follow-on 0
Stages: Series A 1, Series B 1
Remepy $36M Series AQuantHealth $45M Series BNew companies 2 · Follow-on 0
Stages: Series A 2
Beyang Therapeutics $30M Series ACORE Biomedicine $21M Series ANew companies 2 · Follow-on 0
Stages: Series B 1, Series C+ 1
Epicrispr Biotechnologies $90M Series CCrystalys Therapeutics $130M Series BNew companies 2 · Follow-on 0
Stages: Series C+ 2
Epicrispr Biotechnologies $90M Series CRatio Therapeutics $70M Series CNew companies 2 · Follow-on 0
Stages: Series B 1, Series C+ 1
Epicrispr Biotechnologies $90M Series CDraig Therapeutics $65M Series BNew companies 2 · Follow-on 0
Stages: Growth 1, Series C+ 1
Vedanta Biosciences $60M GrowthTrellis Bioscience $9M Series CNew companies 2 · Follow-on 0
Stages: Series A 1, Series C+ 1
Dash Bio $30M Series AChai Discovery $400M Series CNew companies 2 · Follow-on 0
Stages: Series C+ 2
Ratio Therapeutics $70M Series CAdvanCell $315M Series DNew companies 2 · Follow-on 0
Stages: Series A 1, Series C+ 1
CORE Biomedicine $21M Series ARege Nephro Co $10.6M Series CNew companies 2 · Follow-on 0
Stages: Series B 2
Crystalys Therapeutics $130M Series BDraig Therapeutics $65M Series BNew companies 2 · Follow-on 0
Stages: Series C+ 2
AdvanCell $315M Series DLeo Cancer Care $65M Series DNew companies 2 · Follow-on 0
Stages: Series B 1, Series C+ 1
AdvanCell $315M Series DDraig Therapeutics $65M Series BNew companies 2 · Follow-on 0
Stages: Pre-seed 1, Seed 1
Respiro Diagnostics £1M Pre-SeedHealome Therapeutics £2M Seed“—” in Led means every role for that investor in this period is undisclosed; it does not mean zero leads. New companies counts the first participation in a company in our records; follow-on counts later participation.